Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512580 | 0.82 | HDAC1 (0.41) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL19564470 | 0.82 | HDAC1 (0.38) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL7324378 | 0.81 | DAGLA (0.40) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL18179383 | 0.81 | ALDH1A1 (0.46) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL23193214 | 0.80 | HDAC1 (0.44) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL14845019 | 0.80 | HDAC1 (0.44) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL14587960 | 0.78 | ITGAV (0.39) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL3436851 | 0.75 | RAB9A (0.43) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL9257744 | 0.75 | NPC1 (0.50) | HDAC1HDAC8HDAC6GSK3BDYRK1A | |
| SCHEMBL21376435 | 0.74 | HDAC1 (0.32) | HDAC1HDAC8HDAC6GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | GPR6, GALR3, NTSR1 | HDAC1 4697/4885HDAC8 4192/4885HDAC6 4442/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | HDAC1 4788/4885HDAC8 3927/4885HDAC6 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.